Anita Clayton headshot

Anita Hammer Clayton

Unit: School of Medicine
Department: Department of Psychiatry and NB Sciences
Office location and address
1670 Discovery Dr
Charlottesville, Virginia 22911
University of Virginia, 1982, MD
Residency, Psychiatry, University of Virginia

Dr. Anita Clayton’s clinical practice and research interests focus on women’s mental health and sexual dysfunctions. She is the David C. Wilson Professor and Chair of the Department of Psychiatry and Neurobehavioral Sciences, with a secondary appointment as professor of clinical obstetrics and gynecology. She is board certified in psychiatry and neurology.

Dr. Clayton was born in Pensacola, FL, where her father was stationed as a Navy pilot; she grew up traveling throughout the world for her father’s assignments. She finished high school in Virginia Beach and then attended the University of Virginia for her undergraduate and medical degrees. She also completed her internship and residency in behavioral medicine and psychiatry at UVA. Dr. Clayton then served as a U.S. Navy physician for four years before returning to join the faculty at UVA in 1990.

Married for 34 years, Dr. Clayton has a son, a daughter and three stepsons. She enjoys traveling and the arts.

An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression
Source: Janssen Research & Development, LLC
October 24, 2017 – March 03, 2022
MD-PSYCH DBHDS DJ and Alicia Remastering
Source: Department of Behavioral Health and Developmental
July 01, 2021 – December 31, 2021
Efficacy of the BioWick SureLock Implant for the Reattachment of Soft Tissue to Bone in Subjects Undergoing Rotator Cuff Repairs
Source: The Zimmer Corporation
September 28, 2017 – November 01, 2021
MD-PSYCH Vortioxetine Consulting
Source: Takeda Development Center Americas, Inc.
October 10, 2016 – October 09, 2018
MD-PSCH A Phase III Multicenter Randomized Double-Blind Placebo-Controlled Parallel-Group Trial w/an Open-Label Extension Phase to Evaluate the Efficacy & Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women w/HSDD
Source: PRA Health Sciences
January 20, 2015 – January 20, 2018
MD-PSYC Review of Clinical Study Report for the LuAA21004-318 Study
Source: Takeda Development Center Americas, Inc.
May 23, 2014 – May 22, 2016
Trimel Biopharma TBS-2-2012-01
Source: Medpace, Inc.
October 24, 2012 – October 24, 2015
Effect of Lu AA21004 vs Escitalopram on Sexual Functioning in Adults with MDD
Source: Takeda Pharmaceuticals
October 10, 2011 – October 10, 2014
Study to Evaluate Efficacy of Fixed Doses of Desvenlafaxine Succinate
Source: Pfizer Pharmaceutical Labs.
November 04, 2011 – December 04, 2013
Evaluation of the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women with FSAD and/or HSDD
Source: Palatin Technologies, Inc
August 01, 2011 – September 30, 2013
Protocol TESTW006 Study of the Safety & Efficacy of LibiGel for the Treament of HSDD
Source: BioSante Pharmaceuticals, Inc.
July 06, 2007 – February 15, 2013